Navigation Links
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Date:3/11/2009

2007.

    -- Research and development costs (GAAP). Research and development cost
       increased by 234.8% to RMB12.4 million (US$1.8 million) in the fourth
       quarter 2008 from RMB3.7 million (US$0.5 million) for the same period
       in 2007. Research and development cost increased by 93.2% to RMB22.5
       million (US$3.3 million) in 2008 from RMB11.6 million (US$1.6 million)
       in 2007, with R&D cost as a percentage of total net revenues increasing
       to 9.2% in 2008 from 6.5% in 2007.
    -- Sales, marketing and distribution expenses (GAAP). Sales, marketing and
       distribution expenses increased by 68.8% to RMB38.3 million (US$5.6
       million) in the fourth quarter 2008 from RMB22.7 million (US$3.1
       million) for the same period in 2007. Sales, marketing and distribution
       expenses increased 37.4% to RMB119.8 million (US$17.6 million) for 2008
       from RMB84.2 million (US$11.5 million) for 2007. Sales, marketing and
       distribution expenses as a percentage of total net revenues increased
       to 49.2% in 2008 from 46.7% in 2007.
    -- General and administrative expenses (GAAP). General and administrative
       expenses decreased by 19.2% to RMB6.0 million (US$0.9 million) in the
       fourth quarter 2008 from RMB7.4 million (US$1.0 million) for the same
       period in 2007. General and administrative expenses increased 71.2% to
       RMB31.5 million (US$4.6 million) in 2008 from RMB18.4 million (US$2.4
       million) in 2007. General and administrative expenses as a percentage
       of net revenues increased to 12.9% in 2008 from 10.2% in 2007.

Interest income. The Company recorded net interest income of RMB5.9 million (US$0.9 million) in fourth quarter 2008 as compared RMB9.0 million (US$1.2 million) for the same period in 2007. 3SBio recorded net interest income of RMB24.0 million (US$3.5 million) in 2008 as compared to net interest income of RMB
'/>"/>

SOURCE 3SBio Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related biology technology :

1. 3SBio Inc. Receives Official Recognition as a High-Tech Enterprise
2. 3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
3. 3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
4. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
5. 3SBio Inc. Announces Third Quarter 2008 Results
6. 3SBio Inc. Files for SFDA Approval of NuLeusin
7. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
8. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
9. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
10. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
11. 3SBio Inc. Announces Results of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email: